诚意药业：产品取得注册证，产品名称为“托拉塞米片”

Group 1 - The core point of the article is that Chengyi Pharmaceutical has received approval from the National Medical Products Administration for the registration of Torasemide tablets, which is a significant development for the company [1] - Chengyi Pharmaceutical's revenue composition for the year 2024 is projected to be 99.71% from the pharmaceutical manufacturing sector and 0.29% from other businesses [1] - As of the report, Chengyi Pharmaceutical has a market capitalization of 3.5 billion yuan [1] Group 2 - The article also highlights a concerning trend in the pharmaceutical industry regarding the abuse of pregabalin, marking the first reported case of addiction in China, which raises questions about regulatory oversight [1] - There are vulnerabilities in the online platforms that allow the purchase of medications without proper medical records, indicating a need for scientific evaluation on whether to regulate such substances [1]